Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
